Scientists at Scripps Research have uncovered a potential new strategy for treating eye diseases that affect millions of people around the world, often resulting in blindness.

A newly developed light-sensing protein called the MCO1 opsin restores vision in blind mice when attached to retina bipolar cells using gene therapy.

When the eye isn’t getting enough oxygen in the face of common conditions like premature birth or diabetes, it can result in blindness. Scientists have identified new points where they may be able to enable recovery.

Researchers have discovered a strategy that can potentially address a major challenge to the current treatment for choroidal neovascularization (CNV), an aggressive form of age-related macular degeneration.

Researchers have developed a neural network capable of recognizing retinal tissues during the process of their differentiation in a dish.

In experiments in rats and mice, two Johns Hopkins scientists report the successful use of nanoparticles to deliver gene therapy for blinding eye disease.

Exercise can slow or prevent the development of macular degeneration and may benefit other common causes of vision loss, such as glaucoma and diabetic retinopathy, new research from the University of Virginia suggests.

Progression along an age-related macular degeneration (AMD) severity scale over two years predicts the likelihood of developing late-stage disease five years later.

In a novel approach to gene therapy, scientists funded by the National Eye Institute (NEI) report using gold nanoparticles and light to target specific cells in mouse retina.

National Eye Institute (NEI) researchers profiling epigenomic changes in light-sensing mouse photoreceptors have a clearer picture of how age-related eye diseases may be linked to age-related changes in the regulation of gene expression.